About the Company
relay therapeutics is building the world’s first dedicated drug discovery platform centered on protein motion to discover and develop new medicines that will make a transformative difference for patients. by placing protein motion at the heart of drug discovery, relay is pursuing what it believes will be a fundamental paradigm shift within the pharmaceutical industry, ushering in a new generation of drugs with the potential to improve and extend the lives of millions of patients. headquartered in cambridge, mass., relay therapeutics is a private company launched in 2016. to date, relay therapeutics has raised $120m in financing from third rock ventures, bvf partners, gv (formerly google ventures), an affiliate of d.e. shaw research, casdin capital, ecor1 capital, section 32 and alexandria venture investments. our world-class team is equal parts bright and bold, with a shared passion for working in intellectually stimulating environments. if you're creative, collaborative and passionate
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $RLAY News
Does Relay Therapeutics, Inc. (RLAY) Have the Potential to Rally 146.52% as Wall Street Analysts Expect?
Relay Therapeutics, Inc. (RLAY) closed the last trading session at $9.35, gaining 4% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by ...
RLAY Apr 2024 7.500 put
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 146.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong ...
Relay Therapeutics: Platform More Important Than Programs
Relay Therapeutics is developing small molecule drugs for oncology, but its platform has broader applicability. Read why RLAY ...
Commit To Buy Relay Therapeutics At $7.50, Earn 14.5% Annualized Using Options
Investors considering a purchase of Relay Therapeutics Inc (Symbol: RLAY) shares, but tentative about paying the going market price of $9.72/share, might benefit from considering selling puts ...
Relay Therapeutics Inc Ordinary Shares RLAY
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings ...
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Feb. 22, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge ...
Relay Therapeutics: Strong Buy on Improved Financials and Promising Future Milestones
H.C. Wainwright analyst Robert Burns reiterated a Buy rating on Relay Therapeutics (RLAY – Research Report) today and set a price target of $20.00. Robert Burns has given his Buy rating due to a ...
Relay Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
Feb. 22, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational ...
Loading the latest forecasts...